These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 29562511)

  • 1. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
    Cummings J; Fox N; Vellas B; Aisen P; Shan G
    J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining Disease Modifying Therapy for Alzheimer's Disease.
    Cummings J; Fox N
    J Prev Alzheimers Dis; 2017; 4(2):109-115. PubMed ID: 29071250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease drug development pipeline: 2017.
    Cummings J; Lee G; Mortsdorf T; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2017 Sep; 3(3):367-384. PubMed ID: 29067343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.
    Cummings J
    J Neuropsychiatry Clin Neurosci; 2021; 33(1):3-13. PubMed ID: 33108950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease.
    Darby D; Brodtmann A; Woodward M; Budge M; Maruff P
    Int Psychogeriatr; 2011 Nov; 23(9):1376-85. PubMed ID: 21477408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining and labeling disease-modifying treatments for Alzheimer's disease.
    Cummings JL
    Alzheimers Dement; 2009 Sep; 5(5):406-18. PubMed ID: 19751920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The "rights" of precision drug development for Alzheimer's disease.
    Cummings J; Feldman HH; Scheltens P
    Alzheimers Res Ther; 2019 Aug; 11(1):76. PubMed ID: 31470905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
    Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
    Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug development in Alzheimer's disease: the path to 2025.
    Cummings J; Aisen PS; DuBois B; Frölich L; Jack CR; Jones RW; Morris JC; Raskin J; Dowsett SA; Scheltens P
    Alzheimers Res Ther; 2016 Sep; 8():39. PubMed ID: 27646601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current Clinical Trials in the Treatment of Alzheimer's Disease].
    Tamaoka A
    Brain Nerve; 2020 Jan; 72(1):23-34. PubMed ID: 31907330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.
    Wang J; Tan L; Yu JT
    J Alzheimers Dis; 2016; 50(4):927-45. PubMed ID: 26836177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases.
    Parnetti L; Eusebi P; Lleó A
    Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials.
    Bullain S; Doody R
    J Neurochem; 2020 Sep; 155(2):120-136. PubMed ID: 32277473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
    Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
    Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's drug-development pipeline: 2016.
    Cummings J; Morstorf T; Lee G
    Alzheimers Dement (N Y); 2016 Nov; 2(4):222-232. PubMed ID: 29067309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions.
    Andrieu S; Coley N; Lovestone S; Aisen PS; Vellas B
    Lancet Neurol; 2015 Sep; 14(9):926-944. PubMed ID: 26213339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease modification and Neuroprotection in neurodegenerative disorders.
    Cummings J
    Transl Neurodegener; 2017; 6():25. PubMed ID: 29021896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.
    Olsson B; Schott JM; Blennow K; Zetterberg H
    Expert Rev Neurother; 2017 Aug; 17(8):767-775. PubMed ID: 28604243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.